Physician profile
Serge Balmir
NPI 1841414216
$5,235.12
in general payments reported to CMS, 2019-2025
26 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $376 · 2021: $272 · 2022: $936 · 2023: $840 · 2024: $726 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,909 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,909.42 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,050.51 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.34 | 2019-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $425.05 | 2022-2023 | Acthar |
| Otsuka America Pharmaceutical, INC. | $405.35 | 2019-2025 | Jynarque, Voyxact |
| Lilly USA, LLC | $361.37 | 2023-2025 | Mounjaro, Zepbound |
| Akebia Therapeutics INC | $337.64 | 2020-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $337.30 | 2023-2025 | |
| Vifor Pharma, INC. | $325.61 | 2019-2024 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $186.18 | 2019-2023 | Velphoro |
| Travere Therapeutics, INC. | $173.49 | 2023-2025 | |
| Amgen INC. | $145.18 | 2024-2025 | Repatha, Tavneos |
| Opko Pharmaceuticals, LLC | $143.95 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $142.95 | 2019-2022 | |
| Horizon Therapeutics Plc | $132.49 | 2022-2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $125.00 | 2025 | Recorlev |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $125.00 | 2019 | |
| Exact Sciences Corporation | $122.43 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $44.99 | 2025 | |
| Ani Pharmaceuticals, INC. | $43.61 | 2023 | Purified Cortrophin Gel |
| Cormedix INC. | $30.41 | 2025 | Defencath |
| Glaxosmithkline, LLC. | $27.78 | 2021 | |
| Agios Pharmaceuticals, INC. | $25.45 | 2025 | Pyrukynd |
| Amarin Pharma, INC. | $24.99 | 2020 | |
| Ardelyx, INC. | $22.64 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $22.50 | 2019 | |
| Pfizer INC. | $19.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serge Balmir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.